Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04562077
Collaborator
(none)
25
1
13
1.9

Study Details

Study Description

Brief Summary

role of surgery in treatment of recurrent brain glioma prognostic factors and outcome measures Role of surgery : In patients with Grade I gliomas, such as pilocytic astrocytomas, resection is potentially curative.

For more diffuse invasive gliomas (Grade II or higher), initial management typically includes maximal safe resection when possible.

Increasing evidence supports an association between extent of resection and prolonged progression-free and overall survival for patients with diffuse gliomas of all types and grades Many studies reported that more that 90%of patients with glioma showed recurrence at the orginal tumor location.

Review the outcomes of re-operation in treatment of recurrent brain gliomas To determine the prognostic factors which can predict which patient would benefit from multiple surgery .

Trail to Improve the outcome of these patients and decrease rate of complications

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    25 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
    Anticipated Study Start Date :
    Oct 1, 2020
    Anticipated Primary Completion Date :
    Nov 1, 2021
    Anticipated Study Completion Date :
    Nov 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. karnofsky performance status [1year]

      A standard way of measuring the ability of cancer patients to perform ordinary tasks. The Karnofsky Performance Status scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities. Karnofsky Performance Status may be used to determine a patient's prognosis, to measure changes in a patient's ability to function, or to decide if a patient could be included in a clinical trial. Also called KPS.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient previously operated and documented as a glioma with clinical and neuroimaging and pathological evidences.

    Patients who will undergo re-operation for treatment of a recurrent brain glioma at the time of study(one year) Histological types : Different histological types of glioma.

    Exclusion Criteria:
    • patients has brain glioma that is de novo patients who are unfit for any neurosurgical interventions. Multicentric recurrent glioma.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Assuit University Hospitals Assiut Egypt

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Study Director: Ahmed AlGhriany, phD, professor of neurosurgery assiut university
    • Study Director: Ahmed AlShanawany, phD, assistant professor of neurosurgery assiut university
    • Principal Investigator: Mohamad S Waer, Resident at department of neurosurgery

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mohamad Sayed Mohamad, assistant lecturer, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04562077
    Other Study ID Numbers:
    • surgery in glioma
    First Posted:
    Sep 24, 2020
    Last Update Posted:
    Sep 24, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 24, 2020